Disorders of Sexual Development (DSD)

Normal Sexual Differentiation in the Fetus

Genetic Sex Determination and the Bipotential Gonad

• Normal gonadal differentiation and sex development depend on a meticulous choreography of endocrine, paracrine, and autocrine signaling pathways, directed by specific genes, epigenetic influences, transcription factors, and hormones.
• Chromosomal composition of the human embryo, specifically the presence of XX or XY, establishes the genetic sex at fertilization and determines whether the bipotential primordial gonad differentiates into a testis or an ovary.
• At approximately 4 to 6 weeks of gestation, the urogenital ridges develop as paired outgrowths of coelomic epithelium on the ventral side of the mesonephros, giving rise to the gonads, adrenal cortex, kidney, and reproductive tract.
• The bipotential state represents a period of pluripotency where genes are poised for either activation or repression, and sex determination depends on cell fate commitment to one pathway while actively repressing the alternative developmental pathway.
• The somatic cells of the bipotential gonad require the expression of several crucial genes, including Wilms tumor 1 (WT1), GATA binding protein 4 (GATA4), and steroidogenic factor 1 (NR5A1/SF1).

Testicular Differentiation

• The binary switch responsible for testicular development is the sex-determining region on the Y (SRY) gene, located on the short arm of the Y chromosome.
• In the human testis, SRY is expressed in supporting cells at approximately 6 weeks of gestation.
• SRY acts as a transcriptional regulator to increase cellular proliferation, attract interstitial cells, and stimulate testicular Sertoli cell differentiation.
• SRY functions in association with other critical genes, such as SOX9, SF-1, and WT1, to direct the undifferentiated gonad to become a testis.
• By 6 to 7 weeks of gestation, SOX9 expression becomes limited to the nuclei of developing Sertoli cells in the 46,XY fetus.
• Following Sertoli cell development, fetal Leydig cells appear around the seventh to eighth week of gestation and begin producing androgens.

Ovarian Differentiation

• In the 46,XX fetus, the bipotential gonad develops into an ovary by about the 10th to 11th week of gestation.
• Ovarian differentiation occurs strictly in the absence of SRY, testosterone, and anti-Mullerian hormone (AMH).
• A 46,XX chromosome complement is necessary, and both the long and short arms of the X chromosome contain genes for normal ovarian development.
• Key genetic factors required for ovarian development include the dosage-sensitive sex reversal gene DAX1, the signaling molecule WNT4, and R-spondin1.
• Activation of the beta-catenin signaling pathway by WNT4 and R-spondin1 permits FOXL2 transcription factor expression, which sustains oocyte and granulosa cell development while actively suppressing Sertoli and Leydig cell differentiation.

Differentiation of Internal Genital Structures

• Both sexes initially possess paired Wolffian (mesonephric) and Mullerian (paramesonephric) ducts.
• In the 46,XY fetus, Sertoli cells express AMH by 7 weeks of gestation.
• AMH binds to its specific receptor (AMH-RII) on the Mullerian duct mesenchymal cells, inducing matrix metalloproteinase expression and causing the regression of the Mullerian ducts (which would otherwise form the fallopian tubes, uterus, and upper vagina).
• By 8 to 12 weeks, placental human chorionic gonadotropin (hCG) stimulates fetal Leydig cells to produce high levels of testosterone.
• Locally produced testosterone stabilizes the ipsilateral Wolffian ducts, promoting their differentiation into the epididymis, vas deferens, and seminal vesicles.
• In the 46,XX fetus, the absence of AMH allows the Mullerian ducts to persist and differentiate into the fallopian tubes, uterus, cervix, and upper third of the vagina.
• In the absence of fetal testosterone, the Wolffian ducts regress.

Differentiation of External Genital Structures

• The external genitalia of males and females appear identical early in gestation, originating from bipotential tissues including the genital tubercle, urethral folds, and labioscrotal swellings.
• Complete development of male external genitalia requires dihydrotestosterone (DHT), a highly active androgen metabolite.
• DHT is produced from circulating testosterone by the enzyme 5-alpha-reductase in target tissues, which is necessary to fuse the genital folds to form the penis and scrotum.
• An "alternative backdoor pathway" of steroidogenesis also converts 17-hydroxyprogesterone to DHT without passing through testosterone intermediates; this pathway is critical for normal male external genital development.
• A functional X-linked androgen receptor is absolutely required for testosterone and DHT to induce these male phenotypic changes.
• In the 46,XX fetus, the lack of androgen exposure means the urethral folds and labioscrotal swellings do not fuse, developing instead into the labia minora and labia majora, respectively.
• The genital tubercle forms the clitoris, and canalization of the vaginal plate creates the lower portion of the vagina.
• Estrogen is completely unnecessary for normal prenatal female sexual differentiation, as demonstrated by the normal female genital phenotype seen in 46,XX patients with total aromatase deficiency.

Definition of Intersex / Disorders of Sex Development (DSD)

Concept and Current Terminology

• Disorders of Sex Development (DSD) is defined as a condition in which the development of chromosomal, gonadal, or anatomic sex is atypical.
• It represents a discrepancy among the chromosomal, gonadal, and genital sex of an individual.
• The term DSD encompasses a broad spectrum of clinical presentations where the external genitalia may not appear completely male or completely female (atypical or ambiguous genitalia), or where internal reproductive anatomy does not match the chromosomal sex.
• The medical nomenclature was officially revised following an international consensus conference to eliminate confusing, inaccurate, and derogatory terms.
• Previous terms such as "intersex," "hermaphrodite," "pseudohermaphrodite," and "sex reversal" have been officially replaced by the DSD classification system.
• The revised descriptive classification attempts to be sensitive to patient and parent concerns while providing a framework that integrates advancing molecular genetic information.
• Despite the medical transition to DSD terminology, some individuals and advocacy groups continue to self-identify using the term "intersex" or prefer the phrasing "differences of sex development" rather than "disorders".

Clinical Presentation of Atypical Genitalia

• Atypical genitalia in a newborn include features such as apparent females with clitoromegaly (greater than 1 cm) or inguinal masses.
• In apparent males, atypical features include bilateral cryptorchidism, micropenis (stretched penile length less than 2.5 cm at term), or isolated severe hypospadias (penoscrotal or perineal).
• Any degree of hypospadias associated with cryptorchidism is considered an indicator of atypical genital development requiring evaluation.

Etiological Classification of Disorders of Sex Development (DSD)

Sex Chromosomal DSD

• This category includes patients with abnormal or mosaic sex chromosome karyotypes that affect gonadal and sexual differentiation.
• 45,X (Turner Syndrome and variants): Characterized by complete or partial absence of the second sex chromosome. Patients have female phenotypes, streak ovaries, primary ovarian insufficiency, and somatic stigmata like short stature, webbed neck, and lymphedema.
• 47,XXY (Klinefelter Syndrome and variants): The most common sex chromosomal aneuploidy in males. Features include tall stature, small firm testes, hypergonadotropic hypogonadism, azoospermia, and gynecomastia.
• 45,X/46,XY (Mixed Gonadal Dysgenesis): Exhibits extreme phenotypic variability, ranging from a Turner-like female phenotype to ambiguous genitalia to a normal male phenotype. Typically presents with a unilateral dysgenetic testis and a contralateral streak gonad, along with persistent Mullerian structures. There is an increased risk of gonadoblastoma.
• 46,XX/46,XY (Chimeric): Can result from the amalgamation of two distinct embryos (e.g., after in vitro fertilization) and is a recognized cause of ovotesticular DSD.

46,XY DSD

• This category encompasses genetic males (46,XY) who exhibit undervirilization, ranging from completely female external genitalia to ambiguous genitalia. The etiology remains unidentified in up to 50% of cases.
• Defects in Testicular Development (Gonadal Dysgenesis):
  • XY Pure Gonadal Dysgenesis (Swyer Syndrome): Complete failure of testicular differentiation. Patients have a normal female phenotype, normal Mullerian structures, bilateral streak gonads, and present at puberty with delayed maturation. Often caused by SRY gene mutations or deletions.
  • Partial Gonadal Dysgenesis: Incomplete testicular development resulting in ambiguous genitalia and a mix of Wolffian and Mullerian structures.
  • Denys-Drash and Frasier Syndromes: Caused by mutations in the WT1 gene. Characterized by 46,XY gonadal dysgenesis, ambiguous or female genitalia, severe nephropathy (mesangial sclerosis), and a high risk of Wilms tumor or gonadoblastoma.
  • Campomelic Dysplasia: Caused by heterozygous loss-of-function mutations in the SOX9 gene. Presents with severe skeletal anomalies (bowing of long bones, 11 pairs of ribs) and frequent male-to-female sex reversal.
  • SF-1 (NR5A1) Mutations: Causes 46,XY gonadal dysgenesis and undervirilization, with or without primary adrenal insufficiency.
  • XY Gonadal Agenesis (Vanishing Testes Syndrome): Testes function early in gestation (suppressing Mullerian ducts) but regress before complete virilization, resulting in anorchia, a micropenis, and variable genital ambiguity.
• Deficiency of Testicular Hormones (Androgen Synthesis Defects):
  • Leydig Cell Aplasia / LHCGR Mutations: Inactivating mutations of the LH/hCG receptor prevent Leydig cell testosterone production. 46,XY infants have female or ambiguous external genitalia but lack Mullerian structures because Sertoli cell AMH production is normal.
  • Congenital Lipoid Adrenal Hyperplasia (StAR or CYP11A1 Deficiency): Severe defects in converting cholesterol to pregnenolone, halting all steroidogenesis. 46,XY infants present with life-threatening salt-wasting adrenal crisis and completely female external genitalia.
  • 3-beta-Hydroxysteroid Dehydrogenase Type 2 Deficiency: Impairs synthesis of active androgens. 46,XY infants exhibit undervirilization (hypospadias) and severe salt-wasting.
  • 17-alpha-Hydroxylase/17,20-Lyase (CYP17A1) Deficiency: Blocks testosterone synthesis. 46,XY infants usually have completely female external genitalia, accompanied by severe hypertension and hypokalemia due to accumulated mineralocorticoid precursors.
  • P450 Oxidoreductase (POR) Deficiency: Disrupts multiple CYP enzymes. 46,XY infants are undervirilized, often associated with Antley-Bixler skeletal dysplasia.
  • 17-beta-Hydroxysteroid Dehydrogenase Type 3 Deficiency: Impairs testicular conversion of androstenedione to testosterone. 46,XY infants have female or ambiguous genitalia at birth but undergo profound spontaneous virilization at puberty due to peripheral enzyme activity.
  • Persistent Mullerian Duct Syndrome (PMDS): Caused by defects in the AMH gene or the AMH type II receptor. 46,XY males are fully virilized externally but unexpectedly possess a uterus and fallopian tubes, frequently discovered during hernia repair or cryptorchidism evaluation.
• Defects in Androgen Action:
  • 5-alpha-Reductase Type 2 Deficiency: Inability to convert testosterone to DHT in target tissues. 46,XY infants have female or ambiguous genitalia (clitoris-like phallus, pseudovagina). At puberty, the surge in testosterone and type 1 enzyme activity causes marked virilization, and many patients transition to a male gender identity.
  • Complete Androgen Insensitivity Syndrome (CAIS): Caused by severe inactivating mutations in the X-linked androgen receptor gene. 46,XY patients are phenotypically female at birth, have a blind vaginal pouch, absent uterus, and develop normal breasts at puberty (due to aromatization of testosterone), but lack sexual hair and menstruations.
  • Partial Androgen Insensitivity Syndrome (PAIS): Less severe androgen receptor mutations resulting in a spectrum of undervirilization, from hypospadias to severe ambiguity (Reifenstein syndrome). Characterized by gynecomastia and infertility at puberty.
  • Smith-Lemli-Opitz Syndrome: A defect in 7-dehydrocholesterol reductase (DHCR7). Results in impaired cholesterol synthesis. 46,XY infants show genital ambiguity alongside microcephaly, syndactyly of the second and third toes, and intellectual disability.

46,XX DSD

• This category involves genetic females (46,XX) with ovaries who present with varying degrees of virilization of the external genitalia. Internal Mullerian structures (uterus, tubes) are preserved.
• Androgen Excess (Fetal/Fetoplacental Source):
  • 21-Hydroxylase Deficiency (Classic CAH): Accounts for over 90% of 46,XX DSD cases. Reduced cortisol leads to ACTH hypersecretion, massive accumulation of 17-hydroxyprogesterone, and excess adrenal androgen production. 46,XX infants show clitoromegaly and labioscrotal fusion, often presenting with life-threatening salt-wasting crises.
  • 11-beta-Hydroxylase Deficiency: Causes androgen excess and virilization in 46,XX infants, uniquely accompanied by hypertension due to the accumulation of deoxycorticosterone (DOC).
  • 3-beta-Hydroxysteroid Dehydrogenase Type 2 Deficiency: Causes mild to moderate virilization in 46,XX infants due to massive overproduction of the weak androgen DHEA, which is peripherally converted to active androgens.
  • P450 Oxidoreductase (POR) Deficiency: 46,XX infants present with virilization (via the alternative backdoor pathway to DHT) combined with Antley-Bixler skeletal malformations.
  • Aromatase (CYP19A1) Deficiency: Fetal and placental inability to convert androgens to estrogens. 46,XX infants are virilized at birth and experience progressive maternal virilization during the pregnancy. At puberty, the patients fail to feminize and develop hypergonadotropic hypogonadism.
• Androgen Excess (Maternal Source):
  • Maternal Virilizing Tumors: Luteomas of pregnancy, arrhenoblastomas, or Krukenberg tumors can secrete excess androgens that cross the placenta and virilize a 46,XX fetus.
  • Exogenous Androgens/Drugs: Maternal ingestion of androgenic drugs or certain progestins during the critical window of gestation can cause dose-dependent virilization.
• Disorders of Ovarian Development:
  • 46,XX Testicular DSD (XX Male Syndrome): Characterized by a male phenotype with a 46,XX karyotype. Virilization is typically incomplete, and patients are infertile. The vast majority of cases are caused by the abnormal translocation of the SRY gene onto an X chromosome during paternal meiosis.
  • SRY-Negative 46,XX Testicular DSD: Rare cases where SRY is absent; associated with duplications or overexpression of genes like SOX9 or SOX3, resulting in anomalous testicular differentiation in a genetic female.
  • 46,XX Gonadal Dysgenesis: Patients have normal female external genitalia but present with delayed puberty, primary amenorrhea, and streak ovaries due to mutations in genes governing ovarian differentiation (e.g., FSH receptor defects).
• Other / Undetermined Etiology:
  • Mullerian Agenesis (Mayer-Rokitansky-Kuster-Hauser Syndrome): Congenital absence of the uterus and upper vagina with normal ovaries and external female genitalia. Can occur in isolation (Type I) or with renal and skeletal malformations (Type II/MURCS association).
  • Cloacal Exstrophy / VACTERL Association: Complex malformation sequences where ambiguous genitalia result from broad embryological field defects rather than primary endocrine abnormalities.

Ovotesticular DSD

• Historically termed "true hermaphroditism," this DSD is defined strictly by the histological presence of both ovarian tissue with follicles and testicular tissue with seminiferous tubules in the same individual.
• The most common karyotype is 46,XX, though 46,XY and mosaic forms (46,XX/46,XY chimeras) occur.
• The external genitalia are highly variable and ambiguous, and the internal structures usually align with the adjacent gonadal tissue type.
• The gonads may be present as a distinct ovary and a distinct testis on opposite sides, or combined into an ovotestis, which typically shows poor demarcation between the tissues.
• Specific genetic mutations, including those in RSPO1, SF-1, and SOX9, have been identified as molecular causes in some patients.